ArticleBritish journal of cancer2025
Distinct prognostic and molecular profiles of fat versus vein invasion in T3a renal cell carcinoma.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundpT3a renal cell carcinoma (RCC) encompasses three different types of progression features leading to persistent debate on prognostic heterogeneity and the need for reclassification.
methodsData of 1606 patients with pT3aN0/xM0 RCC was analyzed according to the site of invasion (perinephric fat (PFI), sinus fat (SFI), renal vein (RVI), PFI and SFI without RVI (PFI + SFI), and both fat and vein (RVI + FI)) using Kaplan-Meier and Cox proportional hazards methods. RNA sequencing was performed on tumor samples from 19 SFI and 14 RVI patients to identify differentially expressed genes and pathway enrichments.
resultsFive-year DFS were 76%, 68.5%, 62.4%, 63.9%, and 50.1% for SFI, PFI, PFI + SFI, RVI and RVI + FI groups, respectively (p < 0.001). Vein invasion tumors demonstrating consistently poorer survival on size-stratified analysis. Site of invasion was an independent prognostic factor. Transcriptomic profiling revealed that SFI tumors were enriched for epithelial-mesenchymal transition, KRAS signaling, and extracellular matrix reprogramming, whereas RVI tumors exhibited hypoxia, oxidative phosphorylation, and DNA repair pathway activation.
conclusionIn T3a RCC, site of invasion was an independent prognosticator of survival regardless of tumor size. SFI and RVI tumors exhibited distinct genomic and pathway profiles suggesting an intrinsically disparate competencies directing the tumors to adopt different invasion mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.